These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22507797)

  • 1. Stem cell transplantation for multiple myeloma: current and future status.
    Giralt S
    Hematology; 2012 Apr; 17 Suppl 1():S117-20. PubMed ID: 22507797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy of multiple myeloma.
    Kyle RA
    Hematology; 2012 Apr; 17 Suppl 1():S125-8. PubMed ID: 22507799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell transplantation for multiple myeloma: current and future status.
    Giralt S
    Hematology Am Soc Hematol Educ Program; 2011; 2011():191-6. PubMed ID: 22160033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma: treatment evolution.
    San Miguel JF; Mateos MV; Ocio E; Garcia-Sanz R
    Hematology; 2012 Apr; 17 Suppl 1():S3-6. PubMed ID: 22507766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma.
    Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
    Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline treatment of multiple myeloma.
    Fonseca R
    Hematology; 2012 Apr; 17 Suppl 1():S101-4. PubMed ID: 22507793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction therapy in multiple myeloma.
    Harousseau JL
    Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem transplants in the treatment of multiple myeloma. Pro.
    Fassas AB; Tricot G
    Clin Adv Hematol Oncol; 2004 May; 2(5):303-4. PubMed ID: 17682284
    [No Abstract]   [Full Text] [Related]  

  • 13. Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
    Roussel M; Facon T; Moreau P; Harousseau JL; Attal M
    Recent Results Cancer Res; 2011; 183():189-206. PubMed ID: 21509686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New developments in the treatment of patients with multiple myeloma.
    Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
    Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.
    Gao W; Geng C; Zhang L; Li Y; Chen W; Wang C
    Hematology; 2013 Nov; 18(6):341-7. PubMed ID: 23510553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance treatment in multiple myeloma.
    Harousseau JL
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
    [No Abstract]   [Full Text] [Related]  

  • 17. What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?
    Scott E; Reece D
    Hematology Am Soc Hematol Educ Program; 2011; 2011():205-7. PubMed ID: 22160035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatments in multiple myeloma: beyond optimal treatment.
    Harousseau JL
    Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging drugs in multiple myeloma.
    Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.